TOP > 外国特許検索 > REGULATORY T CELL ACTIVATOR, AND USE THEREOF

REGULATORY T CELL ACTIVATOR, AND USE THEREOF NEW

外国特許コード F170009276
整理番号 (S2016-0470-N0)
掲載日 2017年11月7日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP015767
国際公開番号 WO 2017183665
国際出願日 平成29年4月19日(2017.4.19)
国際公開日 平成29年10月26日(2017.10.26)
優先権データ
  • 特願2016-084170 (2016.4.20) JP
発明の名称 (英語) REGULATORY T CELL ACTIVATOR, AND USE THEREOF NEW
発明の概要(英語) A regulatory T cell activator comprising a substance capable of inhibiting the binding between DNAX Accessory Molecule-1 (DNAM-1) and CD155.
特許請求の範囲(英語) [claim1]
1. DNAX Accessory Molecule-1 (DNAM-1) and it consists of the substance which obstructs the connection of CD155, the activator of the controllable T cell.
[claim2]
2. The aforementioned substance which obstructs the connection of DNAM-1 and CD155, the unique cementing material for DNAM-1, the DNAM-1 revelation inhibiter, is the unique cementing material or the CD155 revelation inhibiter for CD155, in claim 1 the activator of the controllable T cell of statement.
[claim3]
3. The transplantation one anti- landlord illness, organ transplant refusals, the autoimmune disease and the tissue conversion disease, it is the inflammation characteristic enteritis or prevention or for remedy of the allergy, in claim 1 or 2 the activator of the controllable T cell of statement.
[claim4]
4. The aforementioned substance which obstructs the connection of DNAM-1 and CD155, DNAM-1 is the unique cementing material which confronts,
The description above DNAM-1 is person DNAM-1,
The aforementioned unique cementing material the antibody or is the fragment,
As for the aforementioned antibody or the fragment, the lymphocyte cell 1x10(5) which you make force make reveal when it reacts with the human DNAM-1 molecule where exists on the cell surface, converting person DNAM-1 to IgG type antibody total length, to be saturated it is possible the aforementioned human DNAM-1 molecule below 100ng
Either of claim 1-3 in one section activator of controllable T cell of statement.
[claim5]
5. The aforementioned substance which obstructs the connection of DNAM-1 and CD155, DNAM-1 is the unique cementing material which confronts,
The description above DNAM-1 is person DNAM-1,
The aforementioned unique cementing material the antibody or is the fragment,
As for the aforementioned antibody or the fragment, person DNAM-1 the lymphocyte cell 1x10(5) which you make force make reveal after being saturated with fusion protein 1000ng of person CD155 and the IgG type antibody constant region, when it reacts, converting the human DNAM-1 molecule where exists on the cell surface, to IgG type antibody total length, below 500ng, to obstruct the connection with the aforementioned fusion protein and the aforementioned human DNAM-1 molecule completely, it is possible
Either of claim 1-4 in one section activator of controllable T cell of statement.
[claim6]
6. The aforementioned antibody is the human type antibody, in claim 4 or 5 the activator of the controllable T cell of statement.
[claim7]
7. As for the aforementioned antibody or the fragment,
The complementary decisive territory (CDR) the 1-3, 1 or several amino acids is deficient at the time of the amino acid arrangement of the respective arrangement number 1-3 or amino acid arranging of the arrangement number 1-3, heavily chain which consists of the amino acid arrangement which it is substituted or is added and variable territory, and CDR1-3, 1 or several amino acids are deficient at the time of the amino acid arrangement of the respective arrangement number 4-6, or amino acid arranging of the arrangement number 4-6 the chain which consists of the amino acid arrangement which it is substituted or is added and variable territory, possess lightly or, or
When it makes connect with person DNAM-1, CDR1-3, heavily chain which consists of the amino acid arrangement of the respective arrangement number 1-3 variable territory, and CDR1-3, competes with the antibody which the chain which consists of the amino acid arrangement of the respective arrangement number 4-6 variable territory, it possesses lightly,
Either of claim 4-6 in one section activator of controllable T cell of statement.
[claim8]
8. As for the aforementioned antibody or the fragment,
CDR1-3, 1 or several amino acids is deficient at the time of the amino acid arrangement of the respective arrangement number 1-3 or amino acid arranging of the arrangement number 1-3, heavily chain which consists of the amino acid arrangement which it is substituted or is added and variable territory, and CDR1-3, 1 or several amino acids are deficient at the time of the amino acid arrangement of the respective arrangement number 4-6, or amino acid arranging of the arrangement number 4-6 the chain which consists of the amino acid arrangement which it is substituted or is added and variable territory, possess lightly,
Either of claim 4-7 in one section activator of controllable T cell of statement.
[claim9]
9. Either of the claim 1-8 it includes with the activator of the controllable T cell of statement and the carrier which can be allowed pharmacy to one section, the medicine composition for controllable T cell activation.
[claim10]
10. The lymphocyte cell 1x10(5) which you make force make reveal when it reacts with the human DNAM-1 molecule where exists on the cell surface, converting person DNAM-1 to IgG type antibody total length, to be saturated it is possible the aforementioned human DNAM-1 molecule below 50ng the anti- human DNAM-1 monoclonal antibody or the fragment.
[claim11]
11. The lymphocyte cell 1x10(5) which you make force make reveal person DNAM-1 after being saturated with fusion protein 1000ng of person CD155 and the IgG type antibody constant region, when it reacts, converting the human DNAM-1 molecule where exists on the cell surface, to IgG type antibody total length, below 300ng, it is possible to obstruct the connection with the aforementioned fusion protein and the aforementioned human DNAM-1 molecule completely, the anti- human DNAM-1 monoclonal antibody or the fragment.
[claim12]
12. It is the human type antibody or the fragment, in claim 10 or 11 the anti- human DNAM-1 monoclonal antibody or that fragment of statement.
[claim13]
13. CDR1-3, 1 or several amino acids is deficient at the time of the amino acid arrangement of the respective arrangement number 1-3 or amino acid arranging of the arrangement number 1-3, heavily chain which consists of the amino acid arrangement which it is substituted or is added and variable territory, and CDR1-3, 1 or several amino acids are deficient at the time of the amino acid arrangement of the respective arrangement number 4-6, or amino acid arranging of the arrangement number 4-6 the chain which consists of the amino acid arrangement which it is substituted or is added and variable territory, possess lightly or, or
When it makes connect with person DNAM-1, CDR1-3, heavily chain which consists of the amino acid arrangement of the respective arrangement number 1-3 variable territory, and CDR1-3, competes with the antibody which the chain which consists of the amino acid arrangement of the respective arrangement number 4-6 variable territory, it possesses lightly,
Either of claim 10-12 in one section anti- human DNAM-1 monoclonal antibody or the fragment of statement.
[claim14]
14. CDR1-3, 1 or several amino acids is deficient at the time of the amino acid arrangement of the respective arrangement number 1-3 or amino acid arranging of the arrangement number 1-3, heavily chain which consists of the amino acid arrangement which it is substituted or is added and variable territory, and CDR1-3, 1 or several amino acids are deficient at the time of the amino acid arrangement of the respective arrangement number 4-6, or amino acid arranging of the arrangement number 4-6 the chain which consists of the amino acid arrangement which it is substituted or is added and variable territory, possess lightly, either of the claim 10-13 in one section the anti- human DNAM-1 monoclonal antibody or the fragment of statement.
[claim15]
15. CDR1-3 has, heavily chain which consists of the amino acid arrangement of the respective arrangement number 1-3 variable territory, and CDR1-3, the chain which consists of the amino acid arrangement of the respective arrangement number 4-6 variable territory, lightly, either of the claim 10-14 in one section the anti- human DNAM-1 monoclonal antibody or the fragment of statement.
[claim16]
16. 1 or several amino acids is deficient at the time of the amino acid arrangement of arrangement number, 7 or amino acid arranging of arrangement number 7 is heavy the chain which consists of the amino acid arrangement which it is substituted or is added and variable territory, and,
1 or several amino acids is deficient at the time of the amino acid arrangement of arrangement number, 8 or amino acid arranging of arrangement number 8 the chain which consists of the amino acid arrangement which it is substituted or is added and variable territory, possesses lightly, either of the claim 10-15 in one section the anti- human DNAM-1 monoclonal antibody or the fragment of statement.
[claim17]
17. Heavily the chain which consists of the amino acid arrangement of arrangement number 7 variable territory, and the chain which consists of the amino acid arrangement of arrangement number 8 variable territory, it possesses lightly, in claim 16 the anti- human DNAM-1 monoclonal antibody or the fragment of statement.
[claim18]
18. 1 or several amino acids is deficient at the time of the amino acid arrangement of arrangement number, 9 or amino acid arranging of arrangement number 9 is heavy the chain which consists of the amino acid arrangement which it is substituted or is added and variable territory, and,
1 or several amino acids is deficient at the time of the amino acid arrangement of arrangement number, 10 or amino acid arranging of arrangement number 10 the chain which consists of the amino acid arrangement which it is substituted or is added and variable territory, possesses lightly, either of the claim 10-14 in one section the anti- human DNAM-1 monoclonal antibody or the fragment of statement.
[claim19]
19. Heavily the chain which consists of the amino acid arrangement of arrangement number 9 variable territory, and the chain which consists of the amino acid arrangement of arrangement number 10 variable territory, it possesses lightly, in claim 18 the anti- human DNAM-1 monoclonal antibody or the fragment of statement.
[claim20]
20. Either of the claim 10-19 in one section the nuclear acid which the anti- human DNAM-1 monoclonal antibody or the fragment of statement the cord/code is done.
[claim21]
21. The vector which contains the nuclear acid of statement in claim 20.
[claim22]
22. The transformant which contains the vector of statement in claim 21.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • UNIVERSITY OF TSUKUBA
  • 発明者(英語)
  • SHIBUYA AKIRA
  • SHIBUYA KAZUKO
  • ABE FUMIE
  • HIROCHIKA REI
  • OKUMURA GENKI
国際特許分類(IPC)
指定国 (WO2017183665)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
この特許について質問等ある場合は、電子メールによりご連絡ください。

PAGE TOP

close
close
close
close
close
close